Loading clinical trials...
Loading clinical trials...
An International, Multi Centre, Prospective, Observational Study of Safety, Tolerability and Adherence of Patients With Relapsing Remitting Multiple Sclerosis Administered Interferon Beta-1a (Rebif® New Formulation) in Real Life Settings
Conditions
Interventions
Rebif® New Formulation
Locations
1
Greece
Neurology Clinic, General Hospital of Thessaloniki "G. Papanikolaou"
Thessaloniki, Greece
Start Date
October 1, 2008
Primary Completion Date
June 1, 2011
Completion Date
June 1, 2011
Last Updated
July 31, 2014
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions